Compare
OS Therapies Inc vs Serina Therapeutics, Inc. vs CV Sciences, Inc. vs Adial Pharmaceuticals, Inc.
| Latest fiscal year | OS Therapies Inc OSTX | Serina Therapeutics, Inc. SER | CV Sciences, Inc. CVSI | Adial Pharmaceuticals, Inc. ADIL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $130.0K | $13.79M | n/a |
| Revenue growth (YoY) | n/a | +132.1% | -12.2% | n/a |
| Gross margin | n/a | n/a | 49.0% | n/a |
| Operating margin | n/a | n/m | -3.4% | n/a |
| Net margin | n/a | n/m | -6.9% | n/a |
| Net income | -$28.75M | -$19.18M | -$958.0K | -$7.98M |
| EPS (Diluted) | -$0.98 | -$1.91 | -$0.01 | -$11.93 |
| Operating cash flow | -$14.24M | -$17.95M | -$407.0K | -$6.49M |
| Free cash flow | -$14.70M | -$18.01M | -$516.0K | n/a |
| Cash & equivalents | n/a | $3.06M | n/a | $5.88M |
| Total assets | $6.84M | $6.95M | $6.96M | $6.67M |
| Total liabilities | $11.86M | $6.99M | $5.49M | $1.40M |
| Shareholders' equity | -$6.10M | -$37.0K | $1.47M | $5.28M |
| Return on year-end equity | n/a | n/a | -65.3% | -151.2% |
| Shares outstanding | 37.11M | 10.77M | 184.26M | 1.11M |
Revenue, most recent five fiscal years
| Fiscal year | OS Therapies Inc | Serina Therapeutics, Inc. | CV Sciences, Inc. | Adial Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | n/a | $130.0K Ended 2025-12-31 | $13.79M Ended 2025-12-31 | n/a |
| 1 year earlier | n/a | $56.0K Ended 2024-12-31 | $15.71M Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | $3.15M Ended 2023-12-31 | $16.00M Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | $34.0K Ended 2022-12-31 | $16.20M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $144.0K Ended 2021-12-31 | $20.05M Ended 2021-12-31 | n/a |